| 5.14 0.07 (1.38%) | 04-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.87 | 1-year : | 7.66 |
| Resists | First : | 5.88 | Second : | 6.55 |
| Pivot price | 5.15  |
|||
| Supports | First : | 4.8 | Second : | 3.99 |
| MAs | MA(5) : | 5.11  |
MA(20) : | 5.22 |
| MA(100) : | 5.9 |
MA(250) : | 4.55 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.3 |
| %K %D | K(14,3) : | 44.4 |
D(3) : | 41.6 |
| RSI | RSI(14): 44 |
|||
| 52-week | High : | 7.82 | Low : | 2.76 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TARA ] has closed above bottom band by 48.2%. Bollinger Bands are 68.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 8 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.19 - 5.21 | 5.21 - 5.24 |
| Low: | 4.84 - 4.87 | 4.87 - 4.89 |
| Close: | 5.1 - 5.14 | 5.14 - 5.18 |
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations. It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease. The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020. Protara Therapeutics, Inc. is headquartered in New York, New York.
Mon, 06 Apr 2026
JonesTrading Maintains Protara Therapeutics(TARA.US) With Buy Rating, Maintains Target Price $25 - Moomoo
Thu, 02 Apr 2026
Insider Sell: Jacqueline Zummo Sells 22,598 Shares of Protara Th - GuruFocus
Thu, 02 Apr 2026
Insider Selling: Protara Therapeutics (NASDAQ:TARA) Insider Sells 22,598 Shares of Stock - marketbeat.com
Thu, 02 Apr 2026
Protara (TARA) Chief R&D Officer sells 22,598 shares under 10b5-1 plan - Stock Titan
Tue, 31 Mar 2026
Protara Therapeutics slumps 12%, raises $75M equity at $5.75 per share - MSN
Mon, 30 Mar 2026
Protara Therapeutics Highlights Positive TARA-002 Phase 2 Results - tipranks.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 54 (M) |
| Shares Float | 47 (M) |
| Held by Insiders | 2.1 (%) |
| Held by Institutions | 78.6 (%) |
| Shares Short | 6,400 (K) |
| Shares Short P.Month | 3,310 (K) |
| EPS | -1.35 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.66 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -20.7 % |
| Return on Equity (ttm) | -31.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.19 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -56 (M) |
| Levered Free Cash Flow | -38 (M) |
| PE Ratio | -3.84 |
| PEG Ratio | 0 |
| Price to Book value | 1.4 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.94 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|